411 results
424B5
WINT
Windtree Therapeutics, Inc.
3 Sep 24
Prospectus supplement for primary offering
9:10am
, and the indication and labeling under any such approval;
risks related to manufacturing active pharmaceutical ingredients, drug product, and other materials we … ) Ltd., and its affiliate, Zhaoke Pharmaceutical (Hefei) Co. Ltd., and their ability to successfully source materials, execute necessary clinical
424B5
WINT
Windtree Therapeutics, Inc.
3 Sep 24
Prospectus supplement for primary offering
9:09am
to manufacturing active pharmaceutical ingredients, drug product, and other materials we need;
delays, interruptions or failures in the manufacture … ., and their ability to successfully source materials, execute necessary clinical and regulatory activities in a timely manner, if at all, to support
8-K
EX-99.1
uksydqa1
20 Aug 24
Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates
4:30pm
8-K
EX-10.1
e5jhikx 4f32i1yt14ud
29 Jul 24
Entry into a Material Definitive Agreement
8:33am
8-K
EX-10.1
5k3kw6a
22 Jul 24
Entry into a Material Definitive Agreement
9:25am
8-K
EX-3.1
dtqve qbxr
22 Jul 24
Entry into a Material Definitive Agreement
9:25am
8-K
EX-10.1
ixexi12mahsdae5eqjyn
1 Jul 24
Entry into a Material Definitive Agreement
4:31pm
8-K
EX-99.1
2idfnfe
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am